Company intelligence / Profile preview

Tissue Genesis

Honolulu, Hawaii, United Statestissuegenesis.com ↗

Ownership: Private
Employees: ~8
Development stage: Commercial

Overview

Tissue Genesis has developed automated systems for extracting stromal vascular fraction (SVF) and other adult stem cells from autologous adipose tissue at the point of care. The Icellator platform is designed for rapid, sterile, and efficient isolation of these therapeutic cells. Clinical results have been reported as promising in initial applications, but the technology remains investigational in the United States.

Therapeutic areas: Cardiovascular
Modalities: Cell therapyDevice (cell isolation system)Enzyme-derived cell therapy processing solutionsStromal vascular fraction (SVF) cell therapyAutologous adipose-derived stem cells
Industry: Therapeutic Medical Devices

Partnerships

BioheartBioheart Inc.SpineSmith Partners LPVet-Stem Inc.

Beyond the preview

Go deeper on Tissue Genesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tissue Genesis.

Explore the full profile